Abstract:Systemic and cerebral inflammatory responses are implicated in the pathogenesis of obesity and associated metabolic impairment. While the NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3) inflammasome has been linked to obesity-associated inflammation, whether it contributes to the development or maintenance of obesity is unknown. We provide support for a direct role of saturated fatty acids, such as palmitic acid, as NLRP3 activating stimuli in obese states. To investigate whether NLRP3 activation contributes to the pathogenesis of diet-induced obesity (DIO) in mice, we tested two different clinical-stage NLRP3 inflammasome inhibitors. We demonstrate a contributory role of this key inflammasome to established obesity and associated systemic and cerebral inflammation. By comparing their effects to calorie restriction, we aimed to identify specific NLRP3-sensitive mechanisms contributing to obesity-induced inflammation (as opposed to be those regulated by weight loss per se). In addition, a direct comparison of an NLRP3 inhibitor to a glucagon like peptide-1 receptor agonist, semaglutide (Wegovy), in the DIO model allowed an appreciation of the relative efficacy of these two therapeutic strategies on obesity, its associated systemic inflammatory response, and cerebral gliosis. We show that two structurally distinct, NLRP3 inhibitors, NT-0249 and NT-0796, reverse obesity in the DIO mouse model and that brain exposure appears necessary for efficacy. In support of this, we show that DIO-driven hypothalamic glial fibrillary acidic protein expression is blocked by dosing with NT-0249/NT-0796. While matching weight loss driven by semaglutide or calorie restriction, remarkably, NLRP3 inhibition provided enhanced improvements in disease-relevant biomarkers of acute phase response, cardiovascular inflammation, and lipid metabolism. SIGNIFICANCE STATEMENT Obesity is a global health concern that predisposes individuals to chronic disease such as diabetes and cardiovascular disease at least in part by promoting systemic inflammation. We report that in mice fed a high-fat, obesogenic diet, obesity is reversed by either of two inhibitors of the intracellular inflammatory mediator NLRP3. Furthermore, NLRP3 inhibition reduces both hypothalamic gliosis and circulating biomarkers of cardiovascular disease risk beyond what can be achieved by either the glucagon like peptide-1 agonist semaglutide or calorie restriction alone.

Blockade of the NLRP3 Inflammasome Improves Metabolic Health and Lifespan in Obese Mice.

NLRP3 inflammasome suppression improves longevity and prevents cardiac aging in male mice

Nlrp3 Inflammasome Inhibition By Mcc950 In Aged Mice Improves Health Via Enhanced Autophagy And Ppar Alpha Activity

Pharmacological Blockade of NLRP3 Inflammasome/IL-1β-Positive Loop Mitigates Endothelial Cell Senescence and Dysfunction

An Acetylation Switch of the NLRP3 Inflammasome Regulates Aging-Associated Chronic Inflammation and Insulin Resistance.

Targeting the NLRP3 Inflammasome to Reduce Diet-induced Metabolic Abnormalities in Mice

NLRP3-inflammasome Inhibition Prevents High Fat and High Sugar Diets-Induced Heart Damage Through Autophagy Induction.

NLRP3 Inflammasome: Potential Role in Obesity Related Low-Grade Inflammation and Insulin Resistance in Skeletal Muscle

NLRP3 inflammasome deficiency attenuates metabolic disturbances involving alterations in the gut microbial profile in mice exposed to high fat diet

Inhibition of the NLRP3 inflammasome prevents ovarian aging

Lifespan-extending interventions induce consistent patterns of fatty acid oxidation in mouse livers

Calorie restriction and life-extending mutation downregulate miR-34a to facilitate lipid metabolism in the liver

Alpha-ketoglutarate, an endogenous metabolite, extends lifespan and compresses morbidity in aging mice

The Effect of Caloric Restriction on the Increase in Senescence-Associated T Cells and Metabolic Disorders in Aged Mice

The metabolite alpha-ketobutyrate extends lifespan by promoting peroxisomal function in C. elegans

Enhanced Cardiomyocyte NLRP3 Inflammasome-Mediated Pyroptosis Promotes d-Galactose-Induced Cardiac Aging

Caloric restriction reveals a metabolomic and lipidomic signature in liver of male mice

Reversal of High Fat Diet-Induced Obesity, Systemic Inflammation, and Astrogliosis by the NLRP3 Inflammasome Inhibitors NT-0249 and NT-0796

AMP-Activated Protein Kinase Regulation of the NLRP3 Inflammasome during Aging

CSF1R inhibitor PLX5622 and environmental enrichment additively improve metabolic outcomes in middle-aged female mice

Dietary Restriction Extends Lifespan through Metabolic Regulation of Innate Immunity